In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trial Results

Summaries of Newsworthy Clinical Trial Results < Back to Main

Page Options

  • Print This Page
  • Email This Document

Search Trial Results

Related Pages

Breast Cancer Trial Results


Sentinel Lymph Node Occult Metastases Have Minimal Survival Effect in Node-Negative Breast Cancer Patients
(Posted: 04/26/2011) - Detailed examination of sentinel lymph node tissue from breast cancer patients revealed previously unidentified metastases in about 16% of the samples, but the difference in 5-year survival between patients with and without these metastases was very small and likely not clinically meaningful. The results were published in the February 3, 2011 New England Journal of Medicine.

Some Women May Not Need More Extensive Lymph Node Surgery for Breast Cancer
(Posted: 03/31/2011) - Results from a randomized clinical trial published February 9, 2011, in the Journal of the American Medical Association demonstrate that axillary lymph node dissection provided no additional survival benefit when compared with sentinel lymph node biopsy in women with small breast tumors and minimal lymph node metastasis who were treated with lumpectomy, whole-breast radiotherapy, and adjuvant systemic therapy.

When Combined with Chemotherapy, Bevacizumab Is Associated with Increased Risk of Death
(Posted: 03/30/2011) - Cancer patients who receive the targeted therapy bevacizumab (Avastin) in combination with chemotherapy are at increased risk of serious side effects that may lead to death, according to a meta-analysis of 16 clinical trials that was published February 2, 2011, in JAMA.

Anastrozole Reduces Recurrence in Early Breast Cancer: 10-Year Results of the ATAC Trial
(Updated: 12/30/2010) - Anastrozole (Arimidex®) is better than tamoxifen (Nolvadex®) at preventing a recurrence of breast cancer in postmenopausal women with early-stage hormone receptor-positive tumors, according to a report published in Lancet Oncology on November 17, 2010.

Lasofoxifene Is Potential New Option for Breast Cancer Risk Reduction
(Posted: 12/07/2010) - An investigational agent in the same family of drugs as tamoxifen and raloxifene may be as or more effective in reducing breast cancer risk in some women. The drug, lasofoxifene, also appears to have important benefits for both bone and heart health and, with one exception, appears to lack the rare but potentially serious side effects associated with tamoxifen and raloxifene, according to results published November 4, 2010, in the Journal of the National Cancer Institute.

< Previous  1 2 3 4 5 6 7 8 9  Next >